Shares of 3D MEDICINES (01244) experienced a rapid surge in early trading, with gains briefly approaching 130%. As of the time of writing, the stock was up 55.05%, trading at HKD 3.38, with a turnover of HKD 8.74 million.

On August 19, Moderna and Merck announced that their Phase 3 clinical trial INTerpath-001, evaluating the tumor neoantigen mRNA vaccine mRNA-4157 in combination with Keytruda as an adjuvant therapy for melanoma, met its primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS). This landmark achievement validated the commercial potential of mRNA technology in oncology, directly igniting the global biotech sector.

Public information shows that 3D MEDICINES has been strategically positioned in the oncology field for years. From the world's first subcutaneous injectable PDL1 to the global first WT1 tumor vaccine, the company has developed its own LNP delivery system and AI-powered tumor vaccine screening platform. Its pipeline, including In-vivo CAR T/NK therapies, targets the most cutting-edge international directions, resonating with the world's leading immuno-oncology developments.

As global cancer immunotherapy enters a new era of gene-based treatments, 3D MEDICINES, with its differentiated pipeline layout and commercial execution pace, is well-positioned to continuously unlock catalysts for valuation re-rating.